Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Keigo Gohda"'
Publikováno v:
Molecules, Vol 24, Iss 22, p 4155 (2019)
The modulators of farnesoid X receptor (FXR), a bile acid receptor, regulate various biological processes including bile acid metabolism, and are associated with the control of fatty liver and osteoporosis. Thus, the control of FXR activity and devel
Externí odkaz:
https://doaj.org/article/61ac62be565e4b98b0703e5e1d8f2c69
Autor:
Takeshi Hiramoto, Yosuke Nonaka, Kazuko Inoue, Takefumi Yamamoto, Mariko Omatsu-Kanbe, Hiroshi Matsuura, Keigo Gohda, Norihisa Fujita
Publikováno v:
Journal of Pharmacological Sciences, Vol 95, Iss 1, Pp 81-93 (2004)
G protein-coupled receptors (GPCRs) are distributed widely throughout the human body, and nearly 50% of current medicines act on a GPCR. GPCRs are considered to consist of seven transmembrane α-helices that form an α-helical bundle in which agonist
Externí odkaz:
https://doaj.org/article/8528c68d9d494f85b4c708ca72a782f5
Autor:
Yukiko Yamashita, Keigo Gohda, Yusuke Iguchi, Ko Fujimori, Keisuke Oda, Arisa Masuda, Mizuho Une, Naoki Teno
Publikováno v:
Bioorganic & Medicinal Chemistry. 85:117238
Autor:
Takie Hiramoto, Tomoko Nishimaki-Mogami, Ko Fujimori, Yukiko Yamashita, Yusuke Iguchi, Keigo Gohda, Keisuke Oda, Arisa Masuda, Mizuho Une, Naoki Teno
Publikováno v:
Bioorganic & Medicinal Chemistry. 27:2220-2227
Antagonizing transcriptional activity of farnesoid X receptor (FXR) in the intestine has been reported as an effective means for the treatment of nonalcoholic fatty liver disease, type 2 diabetes and obesity. We describe herein that the building bloc
Autor:
Arisa Masuda, Keigo Gohda, Naoki Teno, Yusuke Iguchi, Yukiko Yamashita, Keisuke Oda, Ko Fujimori, Mizuho Une
Publikováno v:
ACS Med Chem Lett
[Image: see text] We describe the discovery of analog 15 (FLG249), which is an orally active and nonsteroidal farnesoid X receptor (FXR) antagonist in mice with unique profiles, such as a propensity for ileum distribution and the significant control
Publikováno v:
Bioorganicmedicinal chemistry letters. 41
Farnesoid X receptor (FXR) controls gene-expression relevant to various diseases including nonalcoholic steatohepatitis and has become a drug target to regulate metabolic aberrations. However, some side effects of FXR agonists reported in clinical de
Autor:
Arisa, Masuda, Keigo, Gohda, Yusuke, Iguchi, Ko, Fujimori, Yukiko, Yamashita, Keisuke, Oda, Mizuho, Une, Naoki, Teno
Publikováno v:
Bioorganicmedicinal chemistry. 28(14)
As a cellular bile acid sensor, farnesoid X receptor (FXR) participates in regulation of bile acid, lipid and glucose homeostasis, and liver protection. With respect to the bone metabolism, FXR positively regulates bone metabolism through both bone f
Publikováno v:
Molecules, Vol 24, Iss 22, p 4155 (2019)
Molecules
Volume 24
Issue 22
Molecules
Volume 24
Issue 22
The modulators of farnesoid X receptor (FXR), a bile acid receptor, regulate various biological processes including bile acid metabolism, and are associated with the control of fatty liver and osteoporosis. Thus, the control of FXR activity and devel
Autor:
Keigo Gohda, Ko Fujimori, Yukiko Yamashita, Takie Hiramoto, Naoki Teno, Tomoko Nishimaki-Mogami, Yusuke Iguchi, Mizuho Une
Publikováno v:
ACS Medicinal Chemistry Letters. 9:78-83
Farnesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions
Autor:
Keigo Gohda, Nobuhiro Mori, Naoki Teno, Yusuke Iguchi, Tomoko Nishimaki-Mogami, Mizuho Une, Yukiko Yamashita
Publikováno v:
Bioorganic & Medicinal Chemistry. 25:1787-1794
We describe here a novel chemotype with substituted benzimidazole scaffold for nonsteroidal farnesoid X receptor (FXR) antagonists starting from the identification of a screening hit, BB-4. Structure diversity in four regions A-D of BB-4 or 1 is disc